[Cytokine blockade - a promising therapeutic option in SLE].
Over the last few years evidence on the major pathophysiological role of cytokines in system lupus erythematosus (SLE) has accumulated. Immunological results were recently confirmed by first clinical trials, which suggest that therapies targeted at the proinflammatory cytokines tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, as well as the blockade of Interferon, may be highly effective. Controlled clinical trials will have to prove this concept over the next few years.
Aringer
M
M
Bereich Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus,Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Deutschland. martin.aringer@uniklinikum-dresden.de
Feierl
E
E
Smolen
J
J
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology*; D000093242:Interleukin-6 Inhibitors
D000911:Antibodies, Monoclonal; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors